Tris(1-pentyl-1H-indol-3-yl)methylium chloride induces cytotoxicity in melanoma cell lines in vitro through autophagy
Abstract
Background. We analyzed a cytotoxicity of the synthetized compound LCTA1975 on metastatic skin melanoma cell lines compared with different anticancer drugs. Methods. The cytotoxic activity of LCTA1975 and anticancer drugs (Intaxel, cisplatin and doxorubicin) was assessed on 4 metastatic melanoma cell lines by a MTT test. The apoptosis induction and the cell cycle distribution were analyzed on mel Kor cells by How cytometry. The autophagy activation was assessed using an antibody against LC3B autolysosome marker by immunocytochemistry. results. The cytotoxic activity of LCTA1975 was higher for all used melanoma cell lines than cytotoxic activity of other analyzed anticancer drugs. The apoptosis activation was not detected on mel Kor cell line but a significant number of autophagic cells was observed. Conclusion. LCTA1975 is a perspective compound with pronounced cytotoxicity on metastatic skin melanoma cells with chemoresistance.
About the Authors
E. .. Solomko
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
S. .. Lavrenov
FSBI Gause Institute of New Antibiotics RAMS
Russian Federation
Russian Federation
A. .. Inshakov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
M. .. Abramov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
M. .. Preobrazhenskaya
FSBI Gause Institute of New Antibiotics RAMS
Russian Federation
Russian Federation
E. .. Stepanova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Tsao H., Atkins M.B., Sober A.J. Management of cutaneous melanoma. N. Engl. J. Med. 2004, v. 351, p. 998-1012.
2. Garbe C., Eigentler T.K., Keilholz U., Hauschild A., Kirkwood J.M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011, No. 16, p. 5-24.
3. Riker A.I., Radfar S., Liu S., Wang Y., Khong H.T. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin. Biol. Ther. 2007, No. 7, p. 345-348.
4. Keilholz U., Punt C.J., Gore M. et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 2005, No. 23, p. 6747-6757.
5. Lee M.L., Tomsu K., Von Eschen K.B. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. 2000, No. 10, p. 81-92.
6. Grossman D., Altieri D.C. Drug Resistance in Melanoma: Mechanisms, Apoptosis, and New Potential Therapeutic Targets. Cancer and Metastasis Reviews. 2001, v. 20, No. 1-2, p. 3-11.
7. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene. 2003, No. 22, p. 3138-3151.
8. Zhai S., Yaar M., Doyle S.M., Gilchrest B.A. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp. Cell Res. 1996, No. 224, p. 335-343.
9. McGill G.G., Horstmann M., Widlund H.R. et al. Bcl-2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002, No. 109, p. 707-718.
10. Mizushima N., Klionsky D.J. Protein turnover via autophagy: implications for metabolism. Ann. Rev. Nutr. 2007, No. 27, p. 19-40.
11. Shimizu S., Kanaseki T., Mizushima N. et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 2004, No. 6, p. 1221-1228.
12. Maycotte P., Thorburn A. Autophagy and cancer therapy. Cancer Biology & Therapy. 2011, v. 11, No. 2, p. 127-137.
13. Lavrenov S.N., Luzikov Y.N., Bykov E.E. et al. Synthesis and cytotoxic potency of novel tris(1-alkylindol-3-yl)methylium salts: role of N-alkyl substituents. Bioorg. Med. Chem. 2010, v. 18, No. 18, p. 6905-6913.
14. Степановa Е.В., Штиль A.A., Лавренов С.Н. и соавт. Соли трис(1-алкилиндол-3-ил)метилия - новый класс противоопухолевых соединений. Известия Академии наук. Химическая серия. 2010, № 12, с. 2203-2211.
15. Михайлова И.Н., Лукашина М.И., Барышников А.Ю. и соавт. Клеточные линии меланомы - основа для создания противоопухолевых вакцин. Вестник Российской Академии медицинских наук. 2005, № 7, с. 37-40.
16. Prignano F., Coronnello M., Pimpinelli N., Cappugi P., Mini E., Giannotti B. Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. Cancer Lett. 2002, v. 186, No. 2, p. 183-192.
17. Merighi S., Mirandola P., Varani K. et al. Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. Biochem Pharmacol. 2003, v. 66, No. 5, p. 739-748.
18. Mohith A., Photiou A., Retsas S. The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma. Anticancer Drugs. 1996, v. 7, No. 4, p. 493-498.
Review
For citations:
Solomko E..., Lavrenov S..., Inshakov A..., Abramov M..., Preobrazhenskaya M..., Stepanova E... Tris(1-pentyl-1H-indol-3-yl)methylium chloride induces cytotoxicity in melanoma cell lines in vitro through autophagy. Bone and soft tissue sarcomas, tumors of the skin. 2012;(3):48-53. (In Russ.)
Views:
103
Email this article 
